Pemigatinib in mCRC
Phase II Study of the FGFR Inhibitor Pemigatinib for Previously Treated Metastatic CRC With FGF/FGFR Alterations

Released: January 30, 2023

Expiration: January 29, 2024

Activity

Progress
1
Course Completed